IL-12 based gene therapy in veterinary medicine
- PMID: 23171444
- PMCID: PMC3543347
- DOI: 10.1186/1479-5876-10-234
IL-12 based gene therapy in veterinary medicine
Abstract
The use of large animals as an experimental model for novel treatment techniques has many advantages over the use of laboratory animals, so veterinary medicine is becoming an increasingly important translational bridge between preclinical studies and human medicine. The results of preclinical studies show that gene therapy with therapeutic gene encoding interleukin-12 (IL-12) displays pronounced antitumor effects in various tumor models. A number of different studies employing this therapeutic plasmid, delivered by either viral or non-viral methods, have also been undertaken in veterinary oncology. In cats, adenoviral delivery into soft tissue sarcomas has been employed. In horses, naked plasmid DNA has been delivered by direct intratumoral injection into nodules of metastatic melanoma. In dogs, various types of tumors have been treated with either local or systemic IL-12 electrogene therapy. The results of these studies show that IL-12 based gene therapy elicits a good antitumor effect on spontaneously occurring tumors in large animals, while being safe and well tolerated by the animals. Hopefully, such results will lead to further investigation of this therapy in veterinary medicine and successful translation into human clinical trials.
Figures


Similar articles
-
Cancer electrogene therapy with interleukin-12.Curr Gene Ther. 2010 Aug;10(4):300-11. doi: 10.2174/156652310791823425. Curr Gene Ther. 2010. PMID: 20560875 Review.
-
Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma.Cancer Biol Ther. 2009 Nov;8(22):2114-22. doi: 10.4161/cbt.8.22.9734. Epub 2009 Nov 5. Cancer Biol Ther. 2009. PMID: 19755854
-
Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model.Int J Cancer. 2009 Aug 1;125(3):698-707. doi: 10.1002/ijc.24418. Int J Cancer. 2009. PMID: 19431145
-
Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses.J Immunother. 2011 Jan;34(1):58-64. doi: 10.1097/CJI.0b013e3181fe1997. J Immunother. 2011. PMID: 21150713 Clinical Trial.
-
Electroporation gene therapy preclinical and clinical trials for melanoma.Curr Gene Ther. 2010 Aug;10(4):312-7. doi: 10.2174/156652310791823489. Curr Gene Ther. 2010. PMID: 20557286 Review.
Cited by
-
Clinical trials of immunogene therapy for spontaneous tumors in companion animals.ScientificWorldJournal. 2014;2014:718520. doi: 10.1155/2014/718520. Epub 2014 Nov 17. ScientificWorldJournal. 2014. PMID: 25506617 Free PMC article. Review.
-
Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus.J Transl Genet Genom. 2021;5(4):423-442. doi: 10.20517/jtgg.2021.31. Epub 2021 Dec 5. J Transl Genet Genom. 2021. PMID: 35342877 Free PMC article.
-
Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs.Cancers (Basel). 2021 Feb 13;13(4):785. doi: 10.3390/cancers13040785. Cancers (Basel). 2021. PMID: 33668625 Free PMC article.
-
Meeting Contemporary Challenges: Development of Nanomaterials for Veterinary Medicine.Pharmaceutics. 2023 Sep 15;15(9):2326. doi: 10.3390/pharmaceutics15092326. Pharmaceutics. 2023. PMID: 37765294 Free PMC article. Review.
-
Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas.Neurosurg Focus. 2021 Feb;50(2):E5. doi: 10.3171/2020.11.FOCUS20844. Neurosurg Focus. 2021. PMID: 33524948 Free PMC article.
References
-
- Gardlík R, Pálffy R, Hodosy J, Lukács J, Turna J, Celec P. Vectors and delivery systems in gene therapy. Med Sci Monit. 2005;11:110–121. - PubMed
-
- Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF. T-lymphocyte-directed gene therapy for ADA-SCID: initial trial results. Science. 1995;270:475–480. - PubMed
-
- Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, Merino MJ, Culver K, Miller AD, Blaese RM, Anderson WF. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990;323:570–578. - PubMed
-
- Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255–256. - PubMed
-
- Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metabol. 2003;80:148–158. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous